摘要:
A radiopharmaceutical for diagnostic imaging containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound as a π electron acceptor and a bidentate ligand as a π electron donor and represented by the following formula (I): [99mTc(N)(PNP)(XY)]+ (I)wherein 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand, is markedly accumulated in heart and adrenal glands and hence is useful for radiodiagnostic imaging of heart and adrenal glands.
摘要:
The invention relates to the preparation of complexes of 99m-technetium, 186-rhenium or 188-rhenium usable as radiopharmaceutical products.For this preparation, an oxidized compound of .sup.99m Tc, .sup.186 Re or .sup.188 Re, e.g. an alkali metal or ammonium perrhenate or pertechnetate, is reacted with a first ligand chosen from the group of substituted or unsubstituted, aliphatic and aromatic phosphenes and polyphosphenes and a second nitrogenous ligand constituted by an ammonium nitride or a pharmaceutically acceptable metal or by a nitrogenous compound having a >N--N
摘要:
The present invention relates in general to a method for the reduction of oxygenated compounds of rhenium and technetium and in particular to the reduction of perrhenate or pertechnetate ions.More particularly, the invention relates to reactions for the reduction of the said oxygenated compounds which are carried out in the course of the preparation of complexes of the radionuclides .sup.186 Re, .sup.188 Re and .sup.99m Tc; in these reactions, the radionuclide perrhenate or pertechnetate ion is reduced in the presence of a reducing agent and a ligand which can form a complex with the radionuclide in its reduced oxidation state.
摘要:
The invention relates to a radiopharmaceutical product more particularly having a cardiac tropism, incorporating a nitride complex of a transition metal and the process for the preparation thereof.This complex complies with the formula:(M.ident.N)L.sup.1 L.sup.2 (I)in which M is a transition metal, e.g. Tc99m, Re 186 or Re 188 and L1 and L2, which can be the same or different, comply with the formula: ##STR1## in which R.sup.1 and R.sup.2 can be alkyl radicals, V and W can be O, S or Se, n=0 or 1, m=0 or 1, and Y represents N, P or As.
摘要:
A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [99mTc(N)(PNP)(XY)]+. In this formula, 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand as described in the specification. The compound of the formula is markedly accumulated in heart and adrenal glands and hence is used for radiodiagnostic imaging of heart and adrenal glands.
摘要:
The present invention provides a single radioactive transition metal nitride heterocomplex which permits labeling of a physiologically active substance such as a peptide, hormone or the like without impairing the activity of the substance. The radioactive transition metal nitride heterocomplex of the present invention is represented by the following formula (I): (M≡N)XY (I) wherein a radioactive transition metal M is radioactive technetium or radioactive rhenium, N is a nitrogen atom, X is a diphosphine compound or a diarsine compound, and Y is a bindentate ligand having a combination of electron-donating atoms.